Abstract 397P
Background
In the Nordics, new treatments have emerged, offering targeted therapies tailored to the specific pathophysiology of breast cancer (BC). These therapies are more effective with fewer side effects than conventional chemotherapy. It's crucial to monitor treatment trends, effectiveness, patient selection, and safety closely. The current study aims to study usability and coverage of real-world data among patients with BC in Norway and Denmark with focus on biomarkers in de novo metastatic BC (mBC).
Methods
BC patients were identified in national administrative registers in Denmark and Norway from January 1, 2015 to December 31, 2020 and followed until death or end of follow-up, i.e., December 31, 2021. Patients were categorized according to stage and biomarker status (hormone receptor (HR) and HER2). Descriptive statistics and one-year survival analyses based on Kaplan-Meier were carried out stratified per country, stage and biomarker status.
Results
In total, 51,641 patients with BC were identified (Denmark: 29,392; Norway=22,249), of which 1,988 (3.8%) had mBC at time of diagnosis (Denmark=946 (3.2%); Norway=1,042 (4.7%)). The age at time of diagnosis of mBC was 68.4 in Denmark and 64.4 in Norway. The number and proportions with HR and HER2 combinations in Denmark and Norway, respectively, were HR+/HER2+ 103 (11%) and 58 (5.6%), HR+/HER2- 608 (64%) and 426 (41%), HR-/HER2+ 51 (5%) and 70 (6.7%), HR-/HER2- (i.e., triple negative) 101 (11%) and 102 (10%), not tested 83 (9%) and 386 (37%). One-year survival was highest among mBC patients with HR+/HER2+ status (Denmark= 0.73 (95% confidence interval (CI), 0.65-0.82); Norway= 0.86 (95% CI, 0.80-0.95)) and lowest among those with triple negative mBC (Denmark= 0.52 (95% CI, 0.44-0.63); Norway=0.51 (95% CI, 0.41-0.62)) as expected.
Conclusions
Results are overall in agreement between the two countries with high coverage. This unique data will later be combined with treatment records and becomes highly valuable for real-world evidence studies of targeted treatments in patients with BC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Quantify Research.
Funding
Has not received any funding.
Disclosure
J. Liseth Hansen: Other, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple. M. Johnsen: Other, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple. F. Fischer: Financial Interests, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple. O. Ström: Financial Interests, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple. T. Kopp: Other, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple.
Resources from the same session
393P - A phase II study to evaluate the efficacy and safety of TSL-1502 capsules in breast cancer patients with germline BRCA mutations
Presenter: Bo Lan
Session: Poster session 15
394P - Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC)
Presenter: Paolo Tarantino
Session: Poster session 15
395P - Receptor status heterogeneity during metastatic breast cancer treatment
Presenter: Sandra Geurts
Session: Poster session 15
396P - Evaluation of MUC1-C/CD3 biparatopic-bispecific (BPBS) T cell engager as an immunotherapeutic agent for the treatment of MUC1-expressing metastatic breast cancer (mBC)
Presenter: Ravi Jasuja
Session: Poster session 15
398P - Age and ethnic-driven molecular and clinical disparity of East Asian breast cancers
Presenter: Ji Yoon Lee
Session: Poster session 15
399P - Treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States
Presenter: Shanu Modi
Session: Poster session 15
400P - LncRNA-LINC00294 functions as a ceRNA in regulating JUP through competitively binding to miR-485-5p in breast cancer
Presenter: Ting Yang
Session: Poster session 15
Resources:
Abstract
401P - Evaluation of HER2 scoring in breast carcinoma-stained whole slide images
Presenter: Céline Bossard
Session: Poster session 15
402P - Inflammatory biomarkers for predicting the efficacy of immunotherapy in advanced breast cancer
Presenter: Kuikui Jiang
Session: Poster session 15
403P - Stemness-targeted therapies to inhibit cancer cell plasticity in triple negative breast cancer
Presenter: Andrew Takchi
Session: Poster session 15